What is the recommended management for community-acquired pneumonia in adults, including outpatient and inpatient treatment options?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 23, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Community-Acquired Pneumonia Management

Management of community-acquired pneumonia is stratified by severity and patient risk factors, with outpatient treatment using macrolides or doxycycline for healthy patients, while hospitalized patients require combination therapy with β-lactams plus macrolides or respiratory fluoroquinolones, and ICU patients mandate dual coverage with β-lactams plus either azithromycin or fluoroquinolones. 1

Outpatient Management

Previously Healthy Patients (No Risk Factors for Drug-Resistant S. pneumoniae)

  • First-line: Macrolide (azithromycin, clarithromycin, or erythromycin) 1
  • Alternative: Doxycycline (weaker evidence) 1

Patients with Comorbidities or Risk Factors

Risk factors include chronic heart/lung/liver/renal disease, diabetes, alcoholism, malignancies, asplenia, immunosuppression, or recent antibiotic use (within 3 months) 1

Choose one of the following:

  • Respiratory fluoroquinolone (moxifloxacin, gemifloxacin, or levofloxacin 750 mg) 1
  • β-lactam PLUS macrolide:
    • Preferred β-lactams: High-dose amoxicillin (1 g three times daily) or amoxicillin-clavulanate (2 g twice daily)
    • Alternatives: ceftriaxone, cefpodoxime, cefuroxime (500 mg twice daily)
    • Doxycycline may substitute for the macrolide 1

Important caveat: In regions with high macrolide-resistant S. pneumoniae rates (≥25% with MIC ≥16 mg/mL), use the comorbidity regimen even for previously healthy patients 1

Inpatient Non-ICU Management

Two equally strong options:

  • Respiratory fluoroquinolone (monotherapy) 1
  • β-lactam PLUS macrolide:
    • Preferred β-lactams: cefotaxime, ceftriaxone, or ampicillin
    • Ertapenem for selected patients with gram-negative risk factors (excluding Pseudomonas)
    • Doxycycline may substitute for macrolide 1

For penicillin-allergic patients, use a respiratory fluoroquinolone 1

ICU Management

Standard Severe CAP (No Pseudomonas Risk)

Mandatory combination therapy:

  • β-lactam (cefotaxime, ceftriaxone, or ampicillin-sulbactam)
  • PLUS either:
    • Azithromycin, OR
    • Fluoroquinolone 1

For penicillin allergy: respiratory fluoroquinolone plus aztreonam 1

Pseudomonas Risk Factors Present

Risk factors: structural lung disease, bronchiectasis, chronic/prolonged broad-spectrum antibiotic use (≥7 days in past month), corticosteroid use 1, 2

Choose one regimen:

  1. Antipseudomonal β-lactam (piperacillin-tazobactam, cefepime, imipenem, or meropenem) PLUS ciprofloxacin or levofloxacin 750 mg, OR
  2. Antipseudomonal β-lactam PLUS aminoglycoside PLUS azithromycin, OR
  3. Antipseudomonal β-lactam PLUS aminoglycoside PLUS antipneumococcal fluoroquinolone 1

For penicillin allergy: substitute aztreonam for β-lactam 1

MRSA Risk Factors Present

Add vancomycin or linezolid to the above regimens 1

Antibiotic Duration

Recent 2025 guidelines recommend shorter courses:

  • Outpatients and non-severe hospitalized CAP: Minimum 3 days, less than 5 days total once clinical stability achieved 3, 4
  • Severe CAP (ICU patients): 5 or more days 3, 4

This represents a significant shift from traditional 7-10 day courses, based on newer evidence showing non-inferiority of shorter durations.

Corticosteroid Use

Severe CAP: Corticosteroids may be used (administer within 36 hours of admission) 3, 5

Non-severe CAP: Recommend against routine corticosteroid use 3, 6

The evidence supports corticosteroids only in severe cases to decrease risk of ARDS and shorten treatment duration 5

Diagnostic Testing

Outpatients

Routine diagnostic testing (blood cultures, sputum cultures) is optional 1

Hospitalized Patients

Obtain blood cultures and sputum cultures (if productive cough and quality specimen obtainable) when these high-risk features present:

  • ICU admission
  • Failed outpatient antibiotic therapy
  • Cavitary infiltrates
  • Leukopenia
  • Active alcohol abuse
  • Severe liver disease
  • Asplenia
  • Pleural effusion
  • Positive pneumococcal or Legionella urinary antigen 1

Severe CAP (ICU)

Mandatory testing:

  • Blood cultures
  • Urinary antigens for Legionella and S. pneumoniae
  • Sputum culture (expectorated or endotracheal aspirate if intubated) 1

Timing and Route

First antibiotic dose: Administer while still in emergency department for admitted patients 1

IV to oral switch: Transition when hemodynamically stable, able to take oral medications, and showing clinical improvement 1

Key Pitfalls to Avoid

  1. Don't use macrolide monotherapy in patients with comorbidities or recent antibiotic exposure—resistance rates make this inadequate 1
  2. Don't undertreat ICU patients—combination therapy is mandatory, not optional, for severe CAP 1
  3. Don't continue antibiotics beyond clinical stability—newer evidence supports 3-5 day courses for non-severe CAP 3, 4
  4. Don't forget to cover Pseudomonas in patients with structural lung disease or recent broad-spectrum antibiotic use 1, 2
  5. Don't routinely use corticosteroids in non-severe pneumonia—reserve for severe cases only 3, 6

References

3
Research

2025 guideline updates for community-acquired pneumonia diagnosis and management.

The American journal of emergency medicine, 2026

Related Questions

What is the recommended outpatient treatment for community‑acquired pneumonia in a patient with no pleural, bronchial, cuffing, or perihilar opacities?
What is the recommended outpatient management for a healthy adult ≤65 years old with community-acquired pneumonia and no comorbidities?
What are the recommended outpatient treatment guidelines for community‑acquired pneumonia in patients aged 65 years or older?
What is the recommended inpatient treatment regimen for adult patients with community-acquired pneumonia?
What is the recommended outpatient treatment for low‑risk community‑acquired pneumonia in an otherwise healthy patient under 65 years old with no comorbidities, no recent antibiotic use, and no recent travel or drug‑resistant exposure?
In a 24-year-old Asian female with major depressive disorder who is taking fluoxetine (Prozac) 20 mg daily, is reluctant to increase the dose, and continues to have unstable mood with passive suicidal ideation, what medication can be used to augment fluoxetine for better mood improvement?
Is splaying of the renal pelvicalyceal system dangerous?
What is the recommended augmentation strategy for a 14‑year‑old with persistent depression on fluoxetine 20 mg daily who refuses dose escalation?
What are the names of the randomized controlled trials that support the use of bismuth‑containing quadruple therapy for Helicobacter pylori eradication?
Would lamotrigine (Lamictal) be appropriate for a 14‑year‑old with persistent unipolar depression who is currently taking fluoxetine 20 mg daily and refusing dose escalation?
In a 30-year-old patient with no prior cardiac history presenting with palpitations, what is the most likely electrocardiogram diagnosis?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.